JP2023525020A5 - - Google Patents
Info
- Publication number
- JP2023525020A5 JP2023525020A5 JP2022567422A JP2022567422A JP2023525020A5 JP 2023525020 A5 JP2023525020 A5 JP 2023525020A5 JP 2022567422 A JP2022567422 A JP 2022567422A JP 2022567422 A JP2022567422 A JP 2022567422A JP 2023525020 A5 JP2023525020 A5 JP 2023525020A5
- Authority
- JP
- Japan
- Prior art keywords
- car polypeptide
- cells
- nucleic acid
- car
- polypeptide according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025035520A JP2025102793A (ja) | 2020-05-05 | 2025-03-06 | Ｃｄ２８ゼータ及びｃｄ３ゼータを含むｃａｒ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063020177P | 2020-05-05 | 2020-05-05 | |
| US63/020,177 | 2020-05-05 | ||
| PCT/US2021/030625 WO2021226063A1 (en) | 2020-05-05 | 2021-05-04 | Car comprising cd28 zeta and cd3 zeta |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025035520A Division JP2025102793A (ja) | 2020-05-05 | 2025-03-06 | Ｃｄ２８ゼータ及びｃｄ３ゼータを含むｃａｒ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023525020A JP2023525020A (ja) | 2023-06-14 |
| JP2023525020A5 true JP2023525020A5 (https=) | 2024-05-20 |
| JP7648654B2 JP7648654B2 (ja) | 2025-03-18 |
Family
ID=76181210
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022567422A Active JP7648654B2 (ja) | 2020-05-05 | 2021-05-04 | Ｃｄ２８ゼータ及びｃｄ３ゼータを含むｃａｒ |
| JP2025035520A Pending JP2025102793A (ja) | 2020-05-05 | 2025-03-06 | Ｃｄ２８ゼータ及びｃｄ３ゼータを含むｃａｒ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025035520A Pending JP2025102793A (ja) | 2020-05-05 | 2025-03-06 | Ｃｄ２８ゼータ及びｃｄ３ゼータを含むｃａｒ |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11826386B2 (https=) |
| EP (1) | EP4146697A1 (https=) |
| JP (2) | JP7648654B2 (https=) |
| KR (1) | KR20230025662A (https=) |
| CN (1) | CN115485303A (https=) |
| AU (1) | AU2021266706A1 (https=) |
| BR (1) | BR112022021871A2 (https=) |
| CA (1) | CA3175491A1 (https=) |
| IL (1) | IL297874A (https=) |
| MX (1) | MX2022013898A (https=) |
| TW (1) | TWI886268B (https=) |
| WO (1) | WO2021226063A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7674278B2 (ja) * | 2019-07-03 | 2025-05-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ニューヨーク食道扁平上皮がん１（ｎｙ－ｅｓｏ－１）抗原結合タンパク質およびその使用方法 |
| EP4004049A1 (en) * | 2019-07-24 | 2022-06-01 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors with mage-a4 specificity and uses thereof |
| KR20230025662A (ko) | 2020-05-05 | 2023-02-22 | 리제너론 파마슈티칼스 인코포레이티드 | Cd28 제타 및 cd3 제타를 포함하는 car |
| AU2022271212A1 (en) * | 2021-05-04 | 2023-11-30 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors with mage-a4 specificity and uses thereof |
| CN118995620A (zh) * | 2023-05-16 | 2024-11-22 | 清华大学 | 一种嵌合抗原受体、重组免疫细胞及用途 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| IL79289A (en) | 1985-07-05 | 1992-01-15 | Whitehead Biomedical Inst | Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| ATE117375T1 (de) | 1987-09-11 | 1995-02-15 | Whitehead Biomedical Inst | Transduktionsveränderte fibroblasten und ihre anwendung. |
| JP2914692B2 (ja) | 1987-12-11 | 1999-07-05 | ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ | 内皮細胞の遺伝子修飾 |
| WO1989007136A2 (en) | 1988-02-05 | 1989-08-10 | Whitehead Institute For Biomedical Research | Modified hepatocytes and uses therefor |
| ES2096750T3 (es) | 1990-10-31 | 1997-03-16 | Somatix Therapy Corp | Vectores retroviricos utiles para la terapia genica. |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| EP1068296B1 (en) | 1998-03-31 | 2011-08-10 | Geron Corporation | Compositions for eliciting an immune response to a telomerase antigen |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| KR20030032922A (ko) | 2000-02-24 | 2003-04-26 | 싸이트 테라피스 인코포레이티드 | 세포의 동시 자극 및 농축 |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| AU2002235141A1 (en) | 2000-11-27 | 2002-06-03 | Geron Corporation | Glycosyltransferase vectors for treating cancer |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US9987308B2 (en) | 2011-03-23 | 2018-06-05 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| GB2502127A (en) * | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| WO2015179801A1 (en) * | 2014-05-23 | 2015-11-26 | University Of Florida Research Foundation, Inc. | Car based immunotherapy |
| AU2015312117A1 (en) | 2014-09-02 | 2017-03-02 | Bellicum Pharmaceuticals, Inc. | Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| AU2016306209B2 (en) | 2015-08-07 | 2023-07-06 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Bispecific CAR T-cells for solid tumor targeting |
| CN116731156A (zh) | 2016-03-16 | 2023-09-12 | 伊玛提克斯生物技术有限公司 | 用于癌症免疫治疗的转染t细胞和t细胞受体 |
| US11116834B2 (en) * | 2016-10-19 | 2021-09-14 | City Of Hope | Use of endogenous viral vaccine in chimeric antigen receptor T cell therapy |
| MX2019010906A (es) * | 2017-03-14 | 2020-02-12 | Juno Therapeutics Inc | Metodos para almacenamiento criogenico. |
| WO2018225732A1 (ja) * | 2017-06-05 | 2018-12-13 | 国立大学法人三重大学 | Ｍａｇｅ－ａ４由来ペプチドを認識する抗原結合性タンパク質 |
| JP7416695B2 (ja) * | 2017-12-29 | 2024-01-17 | メモリアル スローン－ケタリング キャンサー センター | 増強されたキメラ抗原受容体およびその使用 |
| EP3966236A4 (en) | 2019-05-07 | 2023-05-10 | The Board of Trustees of the Leland Stanford Junior University | Enhancement of polypeptides and chimeric antigen receptors via hinge domains |
| EP4004049A1 (en) | 2019-07-24 | 2022-06-01 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors with mage-a4 specificity and uses thereof |
| KR20230025662A (ko) | 2020-05-05 | 2023-02-22 | 리제너론 파마슈티칼스 인코포레이티드 | Cd28 제타 및 cd3 제타를 포함하는 car |
-
2021
- 2021-05-04 KR KR1020227042176A patent/KR20230025662A/ko active Pending
- 2021-05-04 EP EP21728685.5A patent/EP4146697A1/en active Pending
- 2021-05-04 CA CA3175491A patent/CA3175491A1/en active Pending
- 2021-05-04 TW TW110116102A patent/TWI886268B/zh active
- 2021-05-04 IL IL297874A patent/IL297874A/en unknown
- 2021-05-04 US US17/307,235 patent/US11826386B2/en active Active
- 2021-05-04 CN CN202180032684.1A patent/CN115485303A/zh active Pending
- 2021-05-04 BR BR112022021871A patent/BR112022021871A2/pt unknown
- 2021-05-04 WO PCT/US2021/030625 patent/WO2021226063A1/en not_active Ceased
- 2021-05-04 JP JP2022567422A patent/JP7648654B2/ja active Active
- 2021-05-04 AU AU2021266706A patent/AU2021266706A1/en active Pending
- 2021-05-04 MX MX2022013898A patent/MX2022013898A/es unknown
-
2023
- 2023-10-20 US US18/382,284 patent/US12291559B2/en active Active
-
2025
- 2025-03-06 JP JP2025035520A patent/JP2025102793A/ja active Pending
- 2025-03-31 US US19/095,648 patent/US20250223334A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023525020A5 (https=) | ||
| JP7026161B2 (ja) | 免疫調節性融合タンパク質およびその使用 | |
| US20240218379A1 (en) | Immunomodulatory fusion proteins and uses thereof | |
| JP2022137020A (ja) | 抗ｃｄ７０キメラ抗原受容体 | |
| US20220169699A1 (en) | Pd-1-cd28 fusion proteins and their use in medicine | |
| CN105940102B (zh) | 抗cd30嵌合抗原受体及其用途 | |
| DK1697399T3 (en) | Human cytotoxic t lymphocyte epitope and its agonist epitope from the non-variable number of muc-1 tandem repeat sequences | |
| JP2019514373A5 (https=) | ||
| JP2022546101A5 (https=) | ||
| JP2019515672A (ja) | 免疫調整性ｉｌ２ｒ融合タンパク質およびその使用 | |
| WO2019136305A1 (en) | Cell-based and immune checkpoint inhibitor therapies combined with il-12 for treating cancer | |
| US20210379149A1 (en) | Increasing or Maintaining T-Cell Subpopulations in Adoptive T-Cell Therapy | |
| JP2021525534A5 (https=) | ||
| JP2023503061A5 (https=) | ||
| WO2020212986A1 (en) | Siglec-based chimeric polypeptides and uses thereof | |
| EP4476246A2 (en) | Recombinant proteins that stimulate an immune response in the presence of naturally inhibitory ligand binding | |
| JP7314161B2 (ja) | ゼータカインにより指向性を付与したＩＬ－１３受容体α２標的Ｔ細胞免疫療法 | |
| US20230348561A1 (en) | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof | |
| US20240075144A1 (en) | Interleukin-37, Chimeric Antigen Receptors, Nucleic Acids, and Vectors Encoding the Same and Uses in Cancer Therapies | |
| JP2024502170A (ja) | 癌のための改良された養子細胞移植療法 | |
| Rodrigues et al. | IL-21 and IL-15 cytokine DNA augments HSV specific effector and memory CD8+ T cell response | |
| WO2023250484A2 (en) | Recombinant interleukin-37, chimeric antigen receptors, nucleic acids, and vectors encoding the same and uses in cancer therapies | |
| Cubitt | Induced CD8α Identifies Enhanced Human NK Cell Il-15-Induced Proliferation and Metabolism and Modulates NK Cell Activation | |
| CA2452172A1 (en) | Methods and compositions for modulating cell activation and uses thereof |